The Missing Ingredient for Big Tech's $3T Recipe?
Big Tech doesn't build everything; they buy what's next. And only Emteq's tech offers real behavior insights for smart glasses, key to unlocking the $3T XR market. Their patented sensors track live facial muscle movements. With health-focused smart glasses in demand, only Emteq has this tech.
FDA requires updated warning about rare heart risk with COVID shots
WASHINGTON (AP) — said Wednesday it has expanded existing warnings on the two leading COVID-19 vaccines about a rare heart side effect mainly seen in young men.
Here's how millions of people could lose health insurance if Trump's tax bill becomes law
WASHINGTON (AP) — Roughly 11.8 million adults and children will be at risk for losing health insurance if Republicans' domestic policy package becomes a law.
How to Hack a $1.3T Market - Ad
Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.
House GOP clears key hurdle on Trump's big bill, pushing it closer to vote
WASHINGTON (AP) — Up all night, House Republicans voted pre-dawn Thursday to advance President Donald Trump's , recouping after GOP leaders worked almost around the clock trying to persuade skeptical holdouts as they race to send the bill to his desk by the Fourth of July deadline.
AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment
AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ivonescimab.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting.
House Republicans race toward a final vote on Trump's tax bill, daring critics to oppose
WASHINGTON (AP) — Republican leaders in the House are sprinting toward a Wednesday vote on President Donald Trump's , determined to seize momentum from a in the Senate while essentially daring members to defy their party's leader and vote against it.
A Historic Gold Announcement Is About to Rock Wall Street - Ad
The greatest investor of all time is about to validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent - and four tiny miners could be your ticket to 100X gains.
FDA Flags Major Safety Concerns For Argenx's Nerve Disorder Drug, Stock Falls
FDA raised safety concerns for Vyvgart Hytrulo in CIDP, while Argenx moves ARGX-119 into late-stage trials for rare neuromuscular disease.
France to ban smoking in parks, beaches, and near schools
PARIS (AP) — France has struggled to kick its . A new public health decree published Saturday aims to change that.
FDA Submission Expected This Summer - Invest Before It Happens - Ad
This company is making heart disease easier to detect with AI. Their tech has officially been designated a "Breakthrough" by the FDA. You now have an opportunity to get in at a potential inflection point.
RFK Jr's CDC Panel Recommends Merck's RSV Shot For Infants
CDC panel backs Merck's Enflonsia for RSV prevention in infants; FDA-approved therapy reduced hospitalizations by 84% in clinical trials.
Bill Gates Says He Knows For A 'Fact' That More Children Will Die Due To US Health Aid Cuts And He's Taking The 'Proof' To Congress
Bill Gates warns that continued U.S. cuts to global health aid could result in 8 million additional child deaths by 2040, urging Congress to reverse course and restore funding to critical programs like PEPFAR and the Global Fund.
Buffett's Next Big Investment... Is It This Gold Play? - Ad
Buffett's $325B cash pile is losing value fast - and one gold miner could be his next move. It trades at a 43% discount to its free cash flow, and fits his criteria to a T. With gold set to soar and valuations stretched, now's your chance to front-run Buffett before August 15.
States can cut off Medicaid funding to Planned Parenthood, the Supreme Court rules
WASHINGTON (AP) — A divided allowed states to cut off Medicaid money to Planned Parenthood in a ruling handed down Thursday amid a wider Republican-backed push to defund the country’s biggest abortion provider.
Senate struggle over Medicaid cuts threatens progress on Trump's big bill
WASHINGTON (AP) — One key unsettled issue stalling progress on in Congress is particularly daunting: How to without harming Americans or the hospitals and others who provide care?
The Missing Ingredient for Big Tech's $3T Recipe? - Ad
Big Tech doesn't build everything; they buy what's next. And only Emteq's tech offers real behavior insights for smart glasses, key to unlocking the $3T XR market. Their patented sensors track live facial muscle movements. With health-focused smart glasses in demand, only Emteq has this tech.
Amarin Lands Massive European Commercialization Deal For Heart Drug Vazkepa, Stock Surges
Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to improve cash flow
HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?
Telehealth company Hims & Hers (HIMS) saw a 34% stock drop after Novo Nordisk (NVO) ended their relationship. Investors must decide if it's a buying opportunity or a warning sign for the industry.
This Coin Could Surge Like Bitcoin Did Back in 2013... - Ad
A new coin is emerging in the crypto world. And investing in it now could end up like Bitcoin or Ethereum during their first bull runs.
Merck's Hypertension Drug Cuts Clinical Worsening Risk In Over 70% Of Patients On Double Background Therapy
Merck's Winrevair reduced clinical worsening in PAH patients in the Phase 3 HYPERION trial, building on prior positive study outcomes.
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns
Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.
The Unlikely Duo Rethinking Wearable Technology - Ad
Why did a surgeon and Snap exec team up? They saw the missing ingredient in the $84T wearables market: behavior. So they built Emteq and invented smart glasses sensors to track real-time expressions, unlocking insights into why we do things. With a $15M term sheet already secured, Emteq is what Big Tech's missing.
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.
Is Elon's Empire Crumbling? - Ad
Jeff Brown - the legend who called Tesla and Nvidia early - says Elon is about to launch a $25T AI revolution. This isn't another chatbot. It's real-world AI that could 14X the impact of ChatGPT. But after July 23rd, it may be too late.
More employers are sending workers shopping for their own health coverage
A small, growing number of employers are putting decisions entirely in the hands of their workers.
A judge could advance Purdue Pharma's $7B opioid settlement after all 50 states back it
All 50 U.S. states have agreed to the OxyContin maker ’s latest plan to settle thousands of lawsuits over the .
Back This Medical AI Tech - Ad
You don't often find healthcare tech company valued at $4M. HeartSciences is an exception. With $75M invested, including R&D, clinical trials, and product development, their patented AI software is approaching FDA submission, a potential major inflection point.
Kraft Heinz pulling certain artificial dyes from its US products in 2027
Kraft Heinz will be pulling certain artificial dyes from its U.S. products starting in 2027 and will no longer roll out new products with the dyes.
Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts
Fired vaccine experts warn that Health Secretary Robert F. Kennedy Jr.'s overhaul of the CDC's key vaccine advisory panel threatens public health and undermines decades of immunization progress, potentially impacting pharmaceutical companies and healthcare markets.
How to Hack a $1.3T Market - Ad
Forget concrete. The new foundation for real estate success is digital, and Pacaso leads the way. Their tech unlocks a $1.3T real estate market. They've already earned $110M+ in gross profits in their operating history and reserved the Nasdaq ticker PCSO.
Supreme Court agrees to hear appeal from New Jersey faith-based pregnancy center
WASHINGTON (AP) — said Monday it will hear from a faith-based pregnancy center in New Jersey challenging a state investigation alleging it misled people into thinking its services included referrals for abortion.
Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy
Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and clinical trial pause.
The Tesla Shock Nobody Sees Coming - Ad
While headlines scream "Tesla is doomed"...Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection
FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis after positive trial data.
Leaders of ‘orgasmic meditation’ women's wellness company OneTaste convicted in forced labor trial
NEW YORK (AP) — The leaders of a sex-focused women’s wellness company that promoted “orgasmic meditation” have been convicted of .
Information, charts or examples are for illustration and educational purposes only and not for individualized investment management This message contains commercial elements, such as advertising. We only send these offers to those who have opted in to our newsletter. Past performance is not indicative of future results. For these reasons we strongly suggest trading in a DEMO/Simulated account. The information provided by us is for educational and informational purposes only. We make no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended and have not determined if the statements and opinions of the advertiser are accurate, correct or truthful. If you use, act upon or make decisions in reliance on information contained or any external source linked within it, you do so at your own peril and agree to hold us, our officers, directors, shareholders, affiliates and agents without fault.